Cisplatin-induced early-onset ototoxicity is linked to hearing loss. The mechanism by which cisplatin causes ototoxicity remains unclear. The purpose of this study was to identify the involvement of receptor-interacting protein kinase (RIP)3-dependent necroptosis in cisplatin-induced ototoxicity in vitro and in vivo. Sprague−Dawley rats (SD, 8 week) were treated via intraperitoneal (i.p.) injection with cisplatin (16 mg/kg for 1 day), and their hearing thresholds were measured by the auditory brainstem response (ABR) method. Hematoxylin and eosin (H & E) staining, immunohistochemistry, and western blots were performed to determine the effect of cisplatin-induced ototoxicity on cochlear morphology. Inhibitor experiments with necros...
Aim: It was aimed to evaluate in-vivo whether darbepoetin-alpha (DPO)application has a preventive ro...
Clinical ototoxicity—permanent hearing loss caused by medications—is estimated to affect millions of...
Aim: It was aimed to evaluate in-vivo whether darbepoetin-alpha (DPO)application has a preventive ro...
SummaryCisplatin is a chemotherapy agent frequently used to treat different types of neoplasia. Otot...
SummaryCisplatin is a chemotherapy agent frequently used to treat different types of neoplasia. Otot...
Cisplatin is a chemotherapeutic drug that causes hearing loss, and the mechanisms of its ototoxicity...
Evidence of significant hearing loss during the early days of use of cisplatin as a chemotherapeutic...
Hearing loss or deafness, in its most serious form, affects an estimated 28 million people in Americ...
Ototoxicity is based on inner ear dysfunction creating hearing loss, balance disorder or both sympto...
AbstractCisplatin-induced ototoxicity remains a primary dose-limiting adverse effect of this highly ...
Hearing loss is a significant health problem that can result from a variety of exogenous insults tha...
Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ mali...
Ototoxicity remains a major dose-limiting side effect of cisplatin. The current studies were carried...
Ototoxicity remains a major dose-limiting side effect of cisplatin. The current studies were carried...
In vitro studies tested the efficacy of three caspase inhibitors, Ac-VAD-cmk (caspase-1 inhibitor), ...
Aim: It was aimed to evaluate in-vivo whether darbepoetin-alpha (DPO)application has a preventive ro...
Clinical ototoxicity—permanent hearing loss caused by medications—is estimated to affect millions of...
Aim: It was aimed to evaluate in-vivo whether darbepoetin-alpha (DPO)application has a preventive ro...
SummaryCisplatin is a chemotherapy agent frequently used to treat different types of neoplasia. Otot...
SummaryCisplatin is a chemotherapy agent frequently used to treat different types of neoplasia. Otot...
Cisplatin is a chemotherapeutic drug that causes hearing loss, and the mechanisms of its ototoxicity...
Evidence of significant hearing loss during the early days of use of cisplatin as a chemotherapeutic...
Hearing loss or deafness, in its most serious form, affects an estimated 28 million people in Americ...
Ototoxicity is based on inner ear dysfunction creating hearing loss, balance disorder or both sympto...
AbstractCisplatin-induced ototoxicity remains a primary dose-limiting adverse effect of this highly ...
Hearing loss is a significant health problem that can result from a variety of exogenous insults tha...
Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ mali...
Ototoxicity remains a major dose-limiting side effect of cisplatin. The current studies were carried...
Ototoxicity remains a major dose-limiting side effect of cisplatin. The current studies were carried...
In vitro studies tested the efficacy of three caspase inhibitors, Ac-VAD-cmk (caspase-1 inhibitor), ...
Aim: It was aimed to evaluate in-vivo whether darbepoetin-alpha (DPO)application has a preventive ro...
Clinical ototoxicity—permanent hearing loss caused by medications—is estimated to affect millions of...
Aim: It was aimed to evaluate in-vivo whether darbepoetin-alpha (DPO)application has a preventive ro...